Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: web + 0.24  Related to the article below (Last Update: 8/4/2008)

Anadarko Announces Second-Quarter Results
WELT ONLINE, Germany -
A replay of the call will also be available on the Web site for approximately 30 days following the conference call. ANADARKO OPERATIONS REPORT For more ...APC - BOM:500312 - WAR:CFL

Earthtimes (press release)
Investor Relations Earnings Release
MarketWatch - Jul 31, 2008
0.24 $ 0.23 $ 0.47 $ 0.45 XCEL ENERGY INC. AND SUBSIDIARIES Notes to Investor Relations Release (Unaudited) Due to the seasonality of Xcel Energy's ...
State Bancorp, Inc. Reports Second Quarter Earnings and Declares ... CNNMoney.com (press release)
Town Sports International Holdings, Inc. Announces Second Quarter ... MarketWatch
Banner Corporation Announces Second Quarter Results; Includes ... MarketWatch
all 1,045 news articles »  BANR - CLUB - XEL

Earthtimes (press release)
Equity One Reports Second Quarter 2008 Operating Results
WELT ONLINE, Germany - Jul 29, 2008
CONFERENCE CALL/WEB CAST INFORMATION We will host a conference call on Wednesday, July 30, 2008, at 9:00 am EST to review the 2008 second quarter earnings ...
Cogdell Spencer Inc. Reports Second Quarter 2008 Financial Results Earthtimes (press release)
all 206 news articles »  EQY - CSA - COL:EQIT
Mexico?s inflation accelerates more than forecast
Tehran Times, Iran - Jul 25, 2008
Core inflation, which excludes some food and energy costs, was also higher than forecast at 0.24 percent. The median estimate of economists for core ...
Builders FirstSource Reports Second Quarter 2008 Results
MarketWatch - Jul 31, 2008
For more information about Builders FirstSource, visit the company's Web site at www.bldr.com. Statements in this news release and the schedules hereto ...BLDR

FLEXNEWS
American National Announces Second Quarter 2008 Results
FOXBusiness - Jul 29, 2008
For more information, including company news and investor relations information, visit the company's web site at http://www.anico.com. ...
Kaydon Corporation Reports Second Quarter Results Barron's Blogs
PSi Technologies Reports Second Quarter 2008 Results NewsBlaze
all 1,243 news articles »  PSIT - KDN - ANAT
About The Internet DNS Flaw
CBS News, NY - Jul 31, 2008
... a phone book or switchboard operator that takes a web address - like cbs.com and translates it to an Internet Protocol (IP) address like 170.20.0.24. ...
TransAlta announces strong second quarter results; on-track to ...
Earthtimes (press release), UK - Jul 31, 2008
A link to the live webcast will be available via TransAlta's website, www.transalta.com, under Web Casts in the Investor Relations section. ...TAC
Percutaneous Spine Biopsy: A Meta-Analysis
Journal of Bone and Joint Surgery (subscription) - Aug 1, 2008
With the numbers available, the adequacy rates (slope = 0.31, p = 0.09) and accuracy rates (slope = 0.24, p = 0.11) of the specimens increased slightly as ...
Want To Save Gas? Try Hypermiling
WBAL TV, MD - Jul 8, 2008
"Just idling, we're using 0.24 gallons per hour," Chafe said. When using air conditioning, "it goes up to 0.33 gallons per hour, so a third of a gallon ...
Source: Google News

Characterizing browsing strategies in the World-Wide web -
LD Catledge, JE Pitkow - Computer Networks and ISDN Systems, 1995 - Elsevier
... Thus, given the estimate of Web servers during the obser- vation period was ... tween
frequency and path length, with the slope across all users equalling -0.24. ...

The anatomy of a large-scale hypertextual Web search engine -
S Brin, L Page - Computer Networks and ISDN Systems, 1998 - Elsevier
... CPU time (\I 0.06 I.66 0.20 I.16 Total time (5 1 0.06 1.80 0.24 I.16 Page 10. ... A
Web search engine is a very rich environment for research ideas. ...

Cost estimation for web applications -
M Ruhe, R Jeffery, I Wieczorek - Software Engineering, 2003. Proceedings. 25th International …, 2003 - ieeexplore.ieee.org
... thirty-five potential cost factors in the area of web development, some of ... of
Requirements 0.10 0.15 0.11 Importance of SW Maintenance 0.19 0.24 0.53 Novelty ...

Measuring the Independence of Central Banks and Its Effect on Policy Outcomes -
A Cukierman, SB Web, B Neyapti - The World Bank Economic Review, 1992 - World Bank
... Legal central bank in- depen- dence" (index) of 0.69 0.64 0.61 0.50 0.48 0.45 0.44
0.42 0.36 0.34 0.33 0.29 0.28 0.27 0.25 0.24 0.24 0.23 0.18 0.17 0.17 ...

The calculation of web impact factors -
P Ingwersen - Journal of Documentation, 1998 - ingentaconnect.com
... inv. WIF /Web- IF Number of websites factor Self-link Ext.-link logic
A web pages www.?bo.fi/ 1.97 0.42 1.55 2.37 0.24 1255 www ...

Real life information retrieval: a study of user queries on the Web -
BJ Jansen, A Spink, J Bateman, T Saracevic - ACM SIGIR Forum, 1998 - portal.acm.org
... Thus, the relevance feedback on the Web is used half as much as in traditional IR
searches. ... 10 185 0.36 9 125 0.24 8 224 0.44 7 484 0.94 6 617 1 5 2,158 4 4 ...

Variation in d 15 N and d 13 C trophic fractionation: implications for aquatic food web studies -
MJ Vander Zanden, JB Rasmussen - Limnology and Oceanography, 2001 - JSTOR
... 0.24 -28.75 ? ... of isotopic fractionation-A literature review produced 35 A8'5N estimates
and 42 A^'3C estimates from 22 studies and 20 species (Web Appendix 1 ...

[PDF] Characterizing Browsing Behaviors on the World-Wide Web -
LD Catledge, JE Pitkow - 1995 - smartech.gatech.edu
... Thus, frequency = -0.24 (path length) This ... Page 6. Characterizing User Browsing
Strategies in the World Wide Web Catledge & Pitkow The ...

Spider Web Protection Through Visual Advertisement: Role of the Stabilimentum -
T EISNER, S NOWICKI - Science, 1983 - sciencemag.org
... responsible for the destruction of un- marked webs, we should be able to wit- ness
early morning bird-web encounters at our study site at the rate of 0.24 186 ...

Topology of the world trade web -
M? Serrano, M Bogun? - Physical Review E, 2003 - APS
... and exponent of the average nearest neighbors degree k , for the world trade web
WTW , the ... RG 179 5287 179 k 43 3.8 43 d 1.8 3.7 1.73 C 0.65 0.24 0.24 2.6 2.2 ...

Source: Google Scholar
 
 

Vaccine For Brain Tumors Shows Promising Results

Article Date: 18 Nov 2006 - 23:00pm (PST)
A vaccine for treating a recurrent cancer of the central nervous system that occurs primarily in the brain, known as glioma, has shown promising results in preliminary data from a clinical trial at UCSF Medical Center.

Findings from the first group of six patients in the study, being conducted at the UCSF Brain Tumor Research Center, showed that vitespen (trademarked as Oncophage), a vaccine made from the patient's own tumor, was associated with tumor-specific immune response in patients with recurrent, high-grade glioma.

Glioma is a type of primary tumor that arises from the glial cells, the connective tissue cells that surround and support nerve cells. The most common site of involvement of a glioma is the brain. Malignant glioma is currently a fatal disease.

The trial results were presented at the Immunotherapy Task Force Meeting, sponsored by the Society of Neuro-Oncology and the Joint Section of Tumors, during the Society's 11th annual scientific meeting in Orlando, Fla., on November 16, 2006.

Article continues below and (thank you)
 
"This is the first documentation of a glioma-specific immune response after vaccination with vitespen," said Andrew T. Parsa, MD, PhD, assistant professor in the UCSF Department of Neurological Surgery and principal investigator of the trial.

"Based on preliminary observation of patients in the first cohort, the tumor-specific immune response evoked by vitespen vaccination may be associated with clinical benefit in these patients with recurrent glioma, including improved progression-free survival and overall survival compared with historical controls. Further studies are certainly warranted to definitively determine the benefit of vitespen in this patient population," he said.

Derived from each individual's tumor, vitespen contains the "fingerprint" of the patient's particular cancer and is designed to reprogram the body's immune system to target only cancer cells bearing this fingerprint. The vaccine is intended to leave healthy tissue unaffected and limit the debilitating side effects typically associated with traditional cancer treatments such as chemotherapy and radiation therapy. Vitespen has been granted fast track and orphan drug designations from the Food and Drug Administration in both metastatic melanoma (skin cancer) and renal cell carcinoma (kidney cancer).
 
The UCSF clinical trial is a phase1/2 study designed to establish the feasibility, safety and preliminary efficacy of vaccination in patients with recurrent, high-grade glioma. The trial involves two groups of six patients, both of which receive a minimum of four injections: the first group receives biweekly vaccinations and the second receives weekly vaccinations. Patients are monitored for immune response before, during and after treatment.

In the first group, study results showed tumor-specific immune response was detected after vaccination in all six patients. Researchers observed that patients whose disease was stable after surgical resection and before vaccination were more likely to respond clinically. Of the first six patients treated, five have exceeded the historical median benchmark of 6.5 months survival from time of recurrence. All six have exceeded the overall survival historical benchmark of 14.6 months from time of diagnosis.

The UCSF investigators will continue to follow patients for progression-free survival and overall survival. According to investigators, no adverse events or toxicity identified were considered attributable to the vaccine. Based on these preliminary findings, a larger phase 2 study is planned for 2007.

Rosalind Hekkala, a 66-year-old woman from Reno, Nev., who was enrolled in the first study group, was originally diagnosed with a brain tumor in July 2005. She had surgery to remove it, but the tumor returned in November. Her daughter learned of the trial at UCSF and Hekkala enrolled. In January 2006 she had another surgery, and this time, the removed tissue was sent to Antigenics, the Massachusetts biotech company that produces the vaccine from the patient's tumor tissue. Because of the size of the tumor, Hekkala will receive injections every other week until mid-February. So far, results are promising with no sign of tumor regrowth, according to the Parsa.

"Every day I feel better," Hekkala said on a recent visit to UCSF to receive her injection. "I set small goals for myself and I keep meeting them. I am very hopeful that this vaccine is the answer."

###

The clinical trial was funded the American Brain Tumor Association and the National Cancer Institute's Specialized Program of Research Excellence.

UCSF is a leading university that advances health worldwide by conducting advanced biomedical research, educating graduate students in the life sciences and health professions, and providing complex patient care.

Contact: Carol Hyman
University of California - San Francisco
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page